Keppra and Hypoxic-ischaemic encephalopathy - a phase IV clinical study of FDA data

Summary:

Hypoxic-ischaemic encephalopathy is reported as a side effect among people who take Keppra (levetiracetam), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Metronidazole, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Hypoxic-ischaemic encephalopathy when taking Keppra. It is created by eHealthMe based on reports of 70,297 people who have side effects when taking Keppra from the FDA, and is updated regularly.

What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.

What is Hypoxic-ischaemic encephalopathy?

Hypoxic-ischaemic encephalopathy (a condition that occurs when the entire brain is deprived of an adequate oxygen supply, but the deprivation isn't total) is found to be associated with 367 drugs and 600 conditions by eHealthMe. Check the latest studies of Hypoxic-ischaemic encephalopathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

70,297 people reported to have side effects when taking Keppra.
Among them, 36 people (0.05%) have Hypoxic-ischaemic encephalopathy.

Could Keppra cause Hypoxic-ischaemic encephalopathy?

Among these 36 people:

How long have people been on Keppra when they have Hypoxic-ischaemic encephalopathy? *

What is the gender of people who have Hypoxic-ischaemic encephalopathy when taking Keppra? *

female: 48.57 %
male: 51.43 %

What is the age of people who have Hypoxic-ischaemic encephalopathy when taking Keppra? *

What are other drugs people take besides Keppra? *

What are other side effects people have besides Hypoxic-ischaemic encephalopathy? *

Cardiac Arrest: 11 people, 30.56%
Cardio-Respiratory Arrest (sudden dysfunction of heart and lungs): 9 people, 25.00%
Nausea And Vomiting: 7 people, 19.44%
Fever: 7 people, 19.44%
Hypotension (abnormally low blood pressure): 6 people, 16.67%
Septic Shock (shock due to blood infection): 6 people, 16.67%
Brain Oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain): 5 people, 13.89%
Consciousness - Decreased: 5 people, 13.89%
Anaemia (lack of blood): 4 people, 11.11%
Acute Kidney Failure: 4 people, 11.11%

What are the existing conditions these people have? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 11.11%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 11.11%
Chest Pain: 3 people, 8.33%
Infection: 2 people, 5.56%
Sleep Disorder: 2 people, 5.56%
Partial Seizures (seizures which affect only a part of the brain at onset): 2 people, 5.56%
Pain: 2 people, 5.56%
Cholecystitis (infection of gallbladder): 2 people, 5.56%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 2.78%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Keppra and have Hypoxic-ischaemic encephalopathy?

- Check whether Hypoxic-ischaemic encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keppra:

Keppra (73,504 reports)

Browse all side effects of Keppra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypoxic-ischaemic encephalopathy:

Hypoxic-ischaemic encephalopathy (367 drugs)

Browse all the conditions that are associated with Hypoxic-ischaemic encephalopathy:

Hypoxic-ischaemic encephalopathy (600 conditions)

Related publications that referenced our studies

Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .
Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on levetiracetam (the active ingredients of Keppra) and Keppra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.